Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as DMT210 Topical Gel 5%
DMT210 5% · 1 trial · 1 indication
Inflammatory lesion counts
Investigator Global Assessment (IGA)
5-point Clinical Erythema Assessment (CEA)
5-point Patient Severity Assessment of Erythema (PSA)
| Arm | Type | Description |
|---|---|---|
| DMT210 Topical Gel | EXPERIMENTAL | DMT210 Topical Gel 5% applied to the face twice daily for 12 weeks |
| Vehicle Control | PLACEBO_COMPARATOR | Topical Gel vehicle applied to the face twice daily for 12 weeks |
| Name | Type | Description |
|---|---|---|
| DMT210 Topical Gel 5% | DRUG | - |
| Vehicle Control | OTHER | - |
Inclusion Criteria: * Patient is male or non-pregnant female at least 18 years of age. * Clinical diagnosis of moderate to severe facial rosacea as determined by Investigator's Global Assessment (IGA) at Randomization * Patient has at least ten inflammatory lesions of rosacea on the face at Randomi...
DMT210 5% is an investigational small molecule topical gel developed by Dermata Therapeutics, Inc. for the treatment of acne rosacea. It is applied to the skin and is being studied as a dermatology therapy. The drug is in Phase 2 clinical development and has not been approved by the FDA.
DMT210 5% is being developed for the treatment of acne rosacea, a chronic inflammatory skin condition. Its only completed clinical study enrolled adults with acne rosacea in the United States. The drug remains investigational and is not approved for any indication.
DMT210 5% is developed by Dermata Therapeutics, Inc., which trades on the Nasdaq under the ticker DRMA. The company is the sponsor of the drug's clinical program in dermatology.
DMT210 5% is in Phase 2 clinical development. One Phase 2 trial has been completed, and no trials are currently active. The drug is investigational and has not received FDA approval.
DMT210 5% has been studied in one completed Phase 2 trial, NCT03003104, titled DMT210 Topical Gel in the Treatment of Acne Rosacea. The trial enrolled 107 participants in the United States, was randomized, double blind, and placebo controlled, and included adults 18 years and older.
Yes, DMT210 5% and DMT210 Topical Gel 5% refer to the same investigational product from Dermata Therapeutics, Inc. The two names describe the same topical gel formulation being studied for acne rosacea.